Influenza virus infections remain a significant disease burden globally causing high levels of acute respiratory infections, morbidity and mortality. Challenge studies (also known as CHIM studies) have previously played an important role in the development of respiratory virus vaccines and treatments. They continue to be a powerful tool to deliver rapid efficacy signals. Here we compare the disease trajectories of a panel of three contemporary influenza challenge viruses, each of a different subtype.
Alex J Mann, Melissa Bevan, Alexander Lima, Nikolay Veselinski, Mariya Kalinova, Charlene Akoto, Kirsty Bradley, Julie Mori, Filipa Rodrigues, Isabel Gonçalves Silva, Asha Patel, Blessing Umoudit, Kingsley Eze, Megan Preston, Sumreen Aftab and Andrew P Catchpole
You can view the poster here.